PBMs, the middlemen in the pharmaceutical supply chain, were originally created to streamline operations and negotiate lower costs for their customers (health insurers). As a result, insurers can ideally pass these savings on to patients in the form of lower premiums and cost-sharing. But PBMs are increasingly putting their own interests ahead of their patients. In recent years, Congress (and numerous presidents) have issued policies limiting PBMs’ influence over supply chains and supply chains. overhead costs. And yet they failed Pass important legislation to control them.
I wrote about this issue in the Public Health Post this week, outlining how PBMs are taking savings away from American patients while Congress sits and watches. Let me go ahead and suggest a few things. national Many of the reforms Congress must pass this session have already been successful. At the national level.
